<DOC>
	<DOCNO>NCT00833963</DOCNO>
	<brief_summary>The MotHER Pregnancy Registry U.S.-based , prospective , observational cohort study woman breast cancer treat herceptin plus perjeta without pertuzumab , ado-trastuzumab emtansine , pregnancy within 7 month prior conception ( regardless cancer stage time trastuzumab , pertuzumab , ado-trastuzumab emtansine exposure ) .</brief_summary>
	<brief_title>An Observational Study Pregnancy And Pregnancy Outcomes Women With Breast Cancer Treated With Herceptin , Perjeta In Combination With Herceptin , Kadcyla During Pregnancy Within 7 Months Prior To Conception ( MotHER )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Pregnant ; woman identify trim pregnancy may enroll study long enrollment occurs prior experience pregnancy outcome Exposure least one dose trastuzumab ( adjuvant metastatic treatment ) , pertuzumab plus trastuzumab combination treatment , adotrastuzumab emtansine pregnancy within 7 month prior conception United States resident Patient provide verbal write informed consent ( behalf behalf child ) Prior knowledge pregnancy outcome time enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Herceptin</keyword>
	<keyword>MBC</keyword>
	<keyword>BC</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>childbirth</keyword>
	<keyword>Perjeta</keyword>
	<keyword>Kadcyla</keyword>
	<keyword>pertuzumab</keyword>
	<keyword>ado-trastuzumab emtansine</keyword>
</DOC>